Among the forty-four patients presented to the study, fifteen achieved complete remission having a small tumor volume less than 5cm and the dose delivered was more than 54 Gy. While, patients who entered in disease progression in both groups were of young age ranging from 20 to 37 years (except one case in group II aged 59 years but grade III pathology).